HNRNPUL2

Summary

HNRNPUL2 (heterogeneous nuclear ribonucleoprotein U like 2, HGNC:25451) is a protein-coding gene on chromosome 11q12.3, encoding Heterogeneous nuclear ribonucleoprotein U-like protein 2 (Q1KMD3). It is a selective cancer dependency (DepMap: 11.0% of cell lines).

Enables RNA binding activity. Predicted to be involved in alternative mRNA splicing, via spliceosome. Located in nucleoplasm.

Source: NCBI Gene 221092 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder (Strong, GenCC)
• Clinical variants (ClinVar): 101 total — 1 pathogenic, 2 likely-pathogenic
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 11.0% of screened cell lines
• MANE Select transcript: NM_001079559

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25451
Approved symbol	HNRNPUL2
Name	heterogeneous nuclear ribonucleoprotein U like 2
Location	11q12.3
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp762N1910
Ensembl gene	ENSG00000214753
Ensembl biotype	protein_coding
Entrez	221092

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 retained_intron

ENST00000301785, ENST00000540127, ENST00000855865, ENST00000855866, ENST00000855867

RefSeq mRNA: 1 — MANE Select: NM_001079559 NM_001079559

CCDS: CCDS41659

Canonical transcript exons

ENST00000301785 — 14 exons

Exon	Start	End
ENSE00001275622	62712630	62715379
ENSE00001403727	62726619	62727457
ENSE00003458718	62724291	62724426
ENSE00003467619	62715500	62715607
ENSE00003486841	62722813	62722903
ENSE00003512824	62721295	62721423
ENSE00003545348	62723914	62723990
ENSE00003561292	62721820	62721942
ENSE00003612025	62722601	62722713
ENSE00003635486	62715864	62715937
ENSE00003656539	62723587	62723726
ENSE00003659479	62720023	62720191
ENSE00003682277	62716989	62717189
ENSE00003685051	62722117	62722380

Expression profiles

Bgee: expression breadth ubiquitous, 274 present calls, max score 97.71.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 46.2117 / max 354.5567, expressed in 1820 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
120226	24.2865	1808
120224	16.1366	1794
120223	1.5960	1021
120225	1.0474	639
120229	0.9964	673
120230	0.8791	585
120227	0.6401	357
120228	0.6297	356

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	97.71	gold quality
Brodmann (1909) area 23	UBERON:0013554	97.69	gold quality
cerebellar vermis	UBERON:0004720	97.28	gold quality
endothelial cell	CL:0000115	97.08	gold quality
primary visual cortex	UBERON:0002436	96.68	gold quality
ventricular zone	UBERON:0003053	96.10	gold quality
tibia	UBERON:0000979	95.96	gold quality
occipital lobe	UBERON:0002021	95.90	gold quality
postcentral gyrus	UBERON:0002581	95.88	gold quality
parietal lobe	UBERON:0001872	95.66	gold quality
cerebellar cortex	UBERON:0002129	95.49	gold quality
ganglionic eminence	UBERON:0004023	95.49	gold quality
superior frontal gyrus	UBERON:0002661	95.45	gold quality
cerebellar hemisphere	UBERON:0002245	95.43	gold quality
skin of hip	UBERON:0001554	95.40	gold quality
cortical plate	UBERON:0005343	95.30	gold quality
entorhinal cortex	UBERON:0002728	95.21	gold quality
medial globus pallidus	UBERON:0002477	95.19	gold quality
lateral nuclear group of thalamus	UBERON:0002736	95.18	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.06	gold quality
globus pallidus	UBERON:0001875	95.05	gold quality
tendon of biceps brachii	UBERON:0008188	95.05	gold quality
cerebellum	UBERON:0002037	95.04	gold quality
lateral globus pallidus	UBERON:0002476	95.04	gold quality
esophagus squamous epithelium	UBERON:0006920	94.96	gold quality
colonic epithelium	UBERON:0000397	94.91	gold quality
upper leg skin	UBERON:0004262	94.62	gold quality
monocyte	CL:0000576	94.61	gold quality
substantia nigra pars compacta	UBERON:0001965	94.47	gold quality
mononuclear cell	CL:0000842	94.44	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.72

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

118 targeting HNRNPUL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777
HSA-MIR-302C-3P	99.89	71.20	1778
HSA-MIR-302D-3P	99.89	71.25	1777
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-369-3P	99.85	70.52	2264

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 11.0% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 2)

• hnRNPUL1 and -2 function downstream of MRN and CtBP-interacting protein (CtIP) to promote recruitment of the BLM helicase to DNA breaks. (PMID:22365830)
• it was demonstrated that CRNDE could form a functional complex with heterogeneous nuclear ribonucleoprotein U-like 2 protein (hnRNPUL2) and direct the transport of hnRNPUL2 between the nucleus and cytoplasm. (PMID:28594403)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:ch211-107m4.1	ENSDARG00000056830
mus_musculus	Hnrnpul2	ENSMUSG00000071659
rattus_norvegicus	Hnrnpul2	ENSRNOG00000019507

Paralogs (2): HNRNPUL1 (ENSG00000105323), HNRNPU (ENSG00000153187)

Protein

Protein identifiers

Heterogeneous nuclear ribonucleoprotein U-like protein 2 — Q1KMD3 (reviewed: Q1KMD3)

Alternative names: Scaffold-attachment factor A2

All UniProt accessions (1): Q1KMD3

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Binds to MLF1 and retains it in the nucleus.

Subcellular location. Nucleus.

RefSeq proteins (1): NP_001073027* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001870	B30.2/SPRY	Domain
IPR003034	SAP_dom	Domain
IPR003877	SPRY_dom	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR035778	SPRY_hnRNP_U	Domain
IPR036361	SAP_dom_sf	Homologous_superfamily
IPR043136	B30.2/SPRY_sf	Homologous_superfamily

Pfam: PF00622, PF02037, PF13671

UniProt features (24 total): modified residue 11, compositionally biased region 8, domain 2, region of interest 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q1KMD3-F1	70.36	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (11): 161, 165, 168, 185, 188, 226, 228, 656, 684, 738, 747

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 103 (showing top): GOBP_ALTERNATIVE_MRNA_SPLICING_VIA_SPLICEOSOME, GOBP_RNA_SPLICING, HU_GENOTOXIN_ACTION_DIRECT_VS_INDIRECT_24HR, GOCC_SYNAPSE, CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_DN, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_TRANS, GOBP_MRNA_PROCESSING, ARID5B_TARGET_GENES, ASH1L_TARGET_GENES, ATF5_TARGET_GENES, GSE10240_IL22_VS_IL17_STIM_PRIMARY_BRONCHIAL_EPITHELIAL_CELLS_UP, BARX1_TARGET_GENES, CIITA_TARGET_GENES, FOXD2_TARGET_GENES, FOXE1_TARGET_GENES

GO Biological Process (1): alternative mRNA splicing, via spliceosome (GO:0000380)

GO Molecular Function (2): RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), membrane (GO:0016020), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
mRNA splicing, via spliceosome	1
nucleic acid binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cell junction	1

Protein interactions and networks

STRING

1194 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HNRNPUL2	HNRNPA0	Q13151	706
HNRNPUL2	FAM98A	Q8NCA5	666
HNRNPUL2	DHX36	Q9H2U1	585
HNRNPUL2	NCBP3	Q53F19	583
HNRNPUL2	HNRNPM	P52272	562
HNRNPUL2	PUF60	Q9UHX1	543
HNRNPUL2	SLU7	O95391	530
HNRNPUL2	PRPF3	O43395	530
HNRNPUL2	NCBP1	Q09161	512
HNRNPUL2	ELAVL2	Q12926	509
HNRNPUL2	SNRNP70	P08621	507
HNRNPUL2	ELAVL3	Q14576	496
HNRNPUL2	ELAVL4	P26378	495
HNRNPUL2	EWSR1	Q01844	492
HNRNPUL2	HNRNPH3	P31942	489

IntAct

218 interactions, top by confidence:

A	B	Type	Score
ANKRD54	TULP3	psi-mi:“MI:0914”(association)	0.930
PRMT8	SYNCRIP	psi-mi:“MI:0914”(association)	0.830
QKI	RBFOX2	psi-mi:“MI:0914”(association)	0.720
FAM136A	RBFOX3	psi-mi:“MI:0914”(association)	0.640
NCBP1	KPNA3	psi-mi:“MI:0914”(association)	0.640
NCBP2	KPNA3	psi-mi:“MI:0914”(association)	0.640
IGF2BP1	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
HNRNPH2	PLOD2	psi-mi:“MI:0914”(association)	0.530
NCBP3	SAP18	psi-mi:“MI:0914”(association)	0.530
N	HNRNPDL	psi-mi:“MI:0914”(association)	0.530
N	RBM47	psi-mi:“MI:0914”(association)	0.530
KPNB1	POM121C	psi-mi:“MI:0914”(association)	0.530
CRYAB	CCDC85C	psi-mi:“MI:0914”(association)	0.530
ELAVL2	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
RBM7	HTATSF1	psi-mi:“MI:0914”(association)	0.530
FBXW11	AHCYL1	psi-mi:“MI:0914”(association)	0.530
ILF2	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
CPSF6	DDX39A	psi-mi:“MI:0914”(association)	0.480
U2SURP	SMNDC1	psi-mi:“MI:0914”(association)	0.480
RBM45	HNRNPDL	psi-mi:“MI:0914”(association)	0.460
Ybx1	MRPS18B	psi-mi:“MI:0915”(physical association)	0.400
MATR3	BCLAF3	psi-mi:“MI:0914”(association)	0.350
HNRNPA1	MATR3	psi-mi:“MI:0914”(association)	0.350
SEC16A	NCOR2	psi-mi:“MI:0914”(association)	0.350
Eif3i	CBX4	psi-mi:“MI:0914”(association)	0.350
FOXB1	DDX39A	psi-mi:“MI:0914”(association)	0.350

BioGRID (340): HNRNPUL2 (Affinity Capture-MS), HNRNPUL2 (Affinity Capture-MS), HNRNPUL2 (Affinity Capture-MS), HNRNPUL2 (Affinity Capture-MS), HNRNPUL2 (Affinity Capture-MS), HNRNPUL2 (Affinity Capture-MS), HNRNPUL2 (Affinity Capture-MS), HNRNPUL2 (Affinity Capture-MS), HNRNPUL2 (Affinity Capture-MS), HNRNPUL2 (Affinity Capture-MS), HNRNPUL2 (Co-fractionation), HNRNPUL2 (Co-fractionation), HNRNPUL2 (Co-fractionation), HNRNPUL2 (Co-fractionation), HNRNPUL2 (Co-fractionation)

ESM2 similar proteins: A2IBH5, O14745, O14976, O70145, O75064, P02522, P02523, P02524, P07318, P07530, P19141, P26998, P43320, P50479, P51511, P52824, P53674, P55165, P62696, P62697, P62698, P98150, Q00653, Q007T1, Q00978, Q05714, Q15599, Q1KMD3, Q28619, Q2LEC2, Q3SZK8, Q3T005, Q3U1Y4, Q3U435, Q4R6G4, Q5RC07, Q5REG4, Q5RKI3, Q5T124, Q6P5E8

Diamond homologs: A1L252, A3KMV8, O94712, P18160, P53076, P69566, Q00PI9, Q1KMD3, Q1LUS8, Q28FM1, Q4Z8K6, Q55CP6, Q6VN19, Q6VN20, Q96S59, Q9PTY5, Q9SIZ8, Q9VNV3, Q00839, Q6IMY8, Q8VDM6, Q8VEK3, Q9BUJ2, A2VD92, Q0IIK5, Q19614, Q4R7L5, Q5NVJ8, Q5XH91, Q641Y8, Q90WU3, Q91VR5, Q92499, A0A5F9C6I2, B0LPN4, D3ZXK7, E9PZQ0, E9Q401, P11716, P16960

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 215 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
mRNA Polyadenylation	25	15.8×	7e-21
FGFR2 alternative splicing	5	15.2×	1e-03
Processing of Capped Intron-Containing Pre-mRNA	22	13.0×	2e-16
mRNA Splicing	15	11.8×	2e-10
mRNA Splicing - Major Pathway	30	11.8×	3e-21
NS1 Mediated Effects on Host Pathways	5	10.3×	4e-03
mRNA 3’-end processing	7	9.9×	4e-04
mRNA Splicing - Minor Pathway	6	9.7×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of cytoplasmic translation	5	26.2×	1e-04
alternative mRNA splicing, via spliceosome	5	17.8×	6e-04
regulation of alternative mRNA splicing, via spliceosome	11	14.2×	7e-08
mRNA transport	10	13.9×	5e-07
ribosomal large subunit biogenesis	5	11.7×	3e-03
mRNA stabilization	6	11.6×	7e-04
mRNA splicing, via spliceosome	23	11.2×	9e-15
RNA processing	9	10.4×	2e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

101 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	2
Uncertain significance	89
Likely benign	7
Benign	1

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
4271569	NM_001079559.3(HNRNPUL2):c.656del (p.Glu219fs)	Pathogenic
2636190	NM_001079559.3(HNRNPUL2):c.223G>T (p.Glu75Ter)	Likely pathogenic
3897583	NM_001079559.3(HNRNPUL2):c.954G>A (p.Trp318Ter)	Likely pathogenic

SpliceAI

2079 predictions. Top by Δscore:

Variant	Effect	Δscore
11:62715219:T:A	donor_gain	1.0000
11:62715380:C:CC	acceptor_gain	1.0000
11:62715491:GATAC:G	donor_loss	1.0000
11:62715492:ATACT:A	donor_loss	1.0000
11:62715493:TACT:T	donor_loss	1.0000
11:62715494:ACTC:A	donor_loss	1.0000
11:62715495:C:CA	donor_loss	1.0000
11:62715496:T:TA	donor_loss	1.0000
11:62715497:C:CC	donor_loss	1.0000
11:62715497:CA:C	donor_loss	1.0000
11:62715498:A:AC	donor_gain	1.0000
11:62715498:ACAT:A	donor_gain	1.0000
11:62715498:ACATC:A	donor_gain	1.0000
11:62715499:C:CA	donor_gain	1.0000
11:62715499:CA:C	donor_gain	1.0000
11:62715499:CAT:C	donor_gain	1.0000
11:62715499:CATC:C	donor_gain	1.0000
11:62715499:CATCC:C	donor_gain	1.0000
11:62715501:T:TA	donor_gain	1.0000
11:62715502:C:A	donor_gain	1.0000
11:62715603:TAACC:T	acceptor_gain	1.0000
11:62715604:AACC:A	acceptor_gain	1.0000
11:62715605:ACC:A	acceptor_gain	1.0000
11:62715606:CC:C	acceptor_gain	1.0000
11:62715606:CCC:C	acceptor_gain	1.0000
11:62715607:CC:C	acceptor_gain	1.0000
11:62715608:C:CA	acceptor_loss	1.0000
11:62715608:C:CC	acceptor_gain	1.0000
11:62715608:C:T	acceptor_gain	1.0000
11:62715608:CTGA:C	acceptor_loss	1.0000

AlphaMissense

4862 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:62717105:A:T	V622D	1.000
11:62721329:G:T	A526D	1.000
11:62721926:C:T	G459E	1.000
11:62721927:C:G	G459R	1.000
11:62721927:C:T	G459R	1.000
11:62724314:G:C	F217L	1.000
11:62724314:G:T	F217L	1.000
11:62724316:A:G	F217L	1.000
11:62727059:A:G	L33P	1.000
11:62727071:A:G	L29P	1.000
11:62727079:C:A	K26N	1.000
11:62727079:C:G	K26N	1.000
11:62727113:A:G	L15P	1.000
11:62727125:A:G	L11P	1.000
11:62717072:A:G	L633P	0.999
11:62717084:G:T	A629E	0.999
11:62717085:C:G	A629P	0.999
11:62717174:G:T	P599H	0.999
11:62717185:G:C	N595K	0.999
11:62717185:G:T	N595K	0.999
11:62720023:C:G	A594P	0.999
11:62720024:T:A	K593N	0.999
11:62720024:T:G	K593N	0.999
11:62720027:C:A	M592I	0.999
11:62720027:C:G	M592I	0.999
11:62720027:C:T	M592I	0.999
11:62720028:A:C	M592R	0.999
11:62720028:A:G	M592T	0.999
11:62720115:A:T	V563D	0.999
11:62720157:A:G	L549P	0.999

dbSNP variants (sampled 300 via entrez): RS1000314782 (11:62713697 C>T), RS1000387734 (11:62716705 G>A), RS1000417515 (11:62716363 A>G), RS1000457536 (11:62719624 G>A), RS1000707265 (11:62727479 C>G,T), RS1000824717 (11:62719841 G>GCC), RS1000826593 (11:62727383 A>C,T), RS1001000852 (11:62728456 G>GA,GT), RS1001239413 (11:62728951 C>T), RS1001471332 (11:62728357 CAAAT>C), RS1001506749 (11:62713035 C>G), RS1001653816 (11:62716864 T>A,C,G), RS1001665242 (11:62719220 C>T), RS1001890832 (11:62727678 C>G,T), RS1002022443 (11:62717004 G>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Strong	Autosomal dominant

Mondo (2): intellectual disability (MONDO:0001071), complex neurodevelopmental disorder (MONDO:0100038)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066501 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 3 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.76	Kd	175.3	nM	CHEMBL5653589
6.76	ED50	175.3	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 4 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148540: Binding affinity to human HNRNPUL2 incubated for 45 mins by Kinobead based pull down assay	kd	0.1753	uM

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression, affects cotreatment, decreases expression	3
bisphenol S	increases expression, increases methylation	2
Valproic Acid	decreases expression, decreases methylation	2
Aflatoxin B1	increases methylation	2
FR900359	increases phosphorylation	1
bisphenol F	increases expression	1
titanium dioxide	increases expression	1
pyrogallol 1,3-dimethyl ether	affects localization, increases expression, affects cotreatment	1
tetrahydropalmatine	increases expression	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
perfluorohexanesulfonic acid	decreases expression	1
nutlin 3	increases secretion, affects cotreatment	1
bisphenol B	increases expression	1
LDN 193189	increases expression, affects cotreatment	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	decreases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Vorinostat	decreases expression	1
Benzo(a)pyrene	decreases expression	1
Caffeine	increases phosphorylation	1
Dactinomycin	affects cotreatment, increases secretion	1
Dexamethasone	affects cotreatment, increases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Folic Acid	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651582	Binding	Binding affinity to human HNRNPUL2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

199 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1